Buteyko Based Remedial Breathing Therapy With Children With Asthma

March 1, 2016 updated by: ARCIM Institute Academic Research in Complementary and Integrative Medicine
A randomized, controlled trial to investigate the effects of a buteyko based remedial breathing therapy on children with asthma regarding to their symptoms, use of medication and lung function tests.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

32

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Germany
    • Baden-Württemberg
      • Filderstadt, Baden-Württemberg, Germany, 70794
        • Filderklinik

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 15 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • signed informed consent of the parents
  • age 6- 15 years
  • information and consent of the consulting doctor
  • levels of asthma therapy 1-3

Exclusion Criteria:

  • participation in another study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Buteyko based Remedial Breathing Therapy
Behavioral: Buteyko based Remedial Breathing Therapy
Buteyko based remedial Breathing Therapy after Dr. Buteyko
No Intervention: Waiting List
Training in the course of the study

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Reduction of Betamimetics (-30%) at 3- and/or 6-month follow up
Time Frame: asthmaspezific parameters are measured before and after intervention as well as 3- and 6- month follow up
asthmaspezific parameters are measured before and after intervention as well as 3- and 6- month follow up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Asthma Control Questionnaire (ACQ)
Time Frame: parameters are measured before and after intervention as well as 3- and 6- month follow up
Scores of the ACQ (Asthma Control Questionnaire)
parameters are measured before and after intervention as well as 3- and 6- month follow up
Paediatric Asthma Quality of Life Questionnaire (PAQLQ)
Time Frame: parameters are measured before and after intervention as well as 3- and 6- month follow up
Scores of PAQLQ (Paediatric Asthma Quality of Life Questionnaire)
parameters are measured before and after intervention as well as 3- and 6- month follow up
ARCIM Questionnaire (AFB)
Time Frame: parameters are measured before and after intervention as well as 3- and 6- month follow up
Scores of the AFB (ARCIM Questionnaire) regarding to asthma symptoms of the last 3 month (AFB is not validated)
parameters are measured before and after intervention as well as 3- and 6- month follow up
Peak Flow
Time Frame: parameters are measured before and after intervention as well as 3- and 6- month follow up
parameters are measured before and after intervention as well as 3- and 6- month follow up
NO-measurement nasal and oral
Time Frame: parameters are measured before and after intervention as well as 3- and 6- month follow up
parameters are measured before and after intervention as well as 3- and 6- month follow up
Buteyko-Questionnaire
Time Frame: parameters are measured before and after intervention as well as 3- and 6- month follow up
parameters are measured before and after intervention as well as 3- and 6- month follow up
parameters of spirometry
Time Frame: parameters are measured before and after intervention as well as 3- and 6- month follow up
parameters are measured before and after intervention as well as 3- and 6- month follow up
Paediatric asthma caregiver´s quality of life questionnaire (PACQLQ)
Time Frame: parameters are measured before and after intervention as well as 3- and 6- month follow up
parameters are measured before and after intervention as well as 3- and 6- month follow up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

ARCIM Institute Academic Research in Complementary and Integrative Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2014

Primary Completion (Actual)

November 1, 2014

Study Completion (Actual)

November 1, 2014

Study Registration Dates

First Submitted

May 14, 2014

First Submitted That Met QC Criteria

May 15, 2014

First Posted (Estimate)

May 16, 2014

Study Record Updates

Last Update Posted (Estimate)

March 2, 2016

Last Update Submitted That Met QC Criteria

March 1, 2016

Last Verified

March 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RBT_03

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Asthma

Clinical Trials on Buteyko based Remedial Breathing Therapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe